Wearable Injectors Market Sees Demand for Large Volume Delivery

The global wearable injectors market was valued at USD 8.80 billion in 2023 and is projected to reach USD 23.89 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.11% from 2024 to 2030. Market growth is primarily driven by the increasing prevalence of chronic diseases, a rapidly aging global population, and heightened awareness regarding the prevention of needle stick injuries among healthcare professionals.

Wearable injectors are gaining traction as a cost-effective and patient-centric alternative to conventional drug delivery methods. The rising emphasis on reducing overall healthcare expenditures, coupled with growing demand for home-based care and continuous drug delivery, is expected to further accelerate market adoption.

Key Market Trends and Insights

• North America emerged as the leading regional market, accounting for 33.2% of global revenue in 2023, supported by advanced healthcare infrastructure and high adoption of innovative drug delivery technologies.
• Asia Pacific is anticipated to register the fastest growth, with a projected CAGR of approximately 18.45% over the forecast period, driven by expanding healthcare access and rising chronic disease burden.
• By technology, the spring-based wearable injectors segment dominated the market with a 35.9% share in 2023 and is expected to maintain its leadership through 2030.
• By application, the oncology segment held the largest share of 29.5% in 2023, reflecting the increasing use of biologics and long-term therapies in cancer treatment.
• By end use, the home care segment led the market with nearly 42.0% revenue share in 2023, highlighting the shift toward self-administration and outpatient care models.

Market Size and Growth

• 2023 Market Size: USD 8.80 Billion
• 2030 Projected Market Size: USD 23.89 Billion
• CAGR (2024–2030): 18.11%
• Largest Market (2023): North America
• Fastest-Growing Region: Asia Pacific

Compared to traditional injectable and intravenous drug delivery methods, wearable injectors offer improved cost efficiency, convenience, and patient safety. Strong healthcare infrastructure and the increasing incidence of lifestyle-related disorders are further contributing to market expansion.

Needle stick injuries (NSIs) remain a significant occupational hazard for healthcare workers and represent a critical driver for the adoption of needle-free or safety-enabled drug delivery solutions. According to a World Health Organization (WHO) study published in 2021, nearly 2 million out of 35 million healthcare professionals worldwide are exposed to occupational injuries annually, increasing the risk of infections such as HIV, hepatitis B, and hepatitis C.

Data from the Centers for Disease Control and Prevention (CDC) and the European Agency for Safety and Health at Work (EU-OSHA) indicate approximately 385,000 and 1,000,000 needle stick injuries annually among healthcare workers in the U.S. and Europe, respectively. WHO estimates further suggest that NSIs result in approximately 16,000 cases of HCV, 66,000 cases of HBV, and 1,000 cases of HIV each year among healthcare workers.

Advanced wearable injector technologies eliminate direct needle contact for patients. Once the device is attached and activated, the needle is automatically inserted, medication delivery is confirmed through tactile, visual, and audible alerts, and the needle retracts and locks upon completion. This design significantly reduces the risk of needle stick injuries compared to conventional parenteral and intravenous administration.

Despite strong growth prospects, market expansion may be constrained by high device costs and relatively lower adoption in developing economies during the forecast period.

Order a free sample PDF of the Wearable Injectors Market Intelligence Study, published by Grand View Research.

Key Companies and Competitive Landscape

The global wearable injectors market is highly fragmented and competitive, with the presence of several established and emerging players. Key market participants are actively pursuing strategies such as new product launches, strategic collaborations, partnerships, mergers and acquisitions, geographic expansion, and patient awareness initiatives.

In March 2021, Aptar and Noble International collaborated with dne pharma to deploy the Unidose Liquid System developed by Ventizolve, Aptar, and Noble, aimed at mitigating opioid overdose risks in Europe. Additionally, biopharmaceutical companies are increasingly adopting wearable injectors for biologic drug delivery. Notable developments include the acquisition of AMF Medical SA by Tandem Diabetes Care, Inc. in January 2023 and the collaboration between Enable Injections, Inc. and Viridian Therapeutics, Inc. in May 2023.

Key Wearable Injectors Companies:

• BD
• Johnson & Johnson Services, Inc.
• Hoffmann-La Roche Ltd.
• Unilife Corporation
• SteadyMed Therapeutics, Inc.
• Amgen Inc.
• Insulet Corporation
• Enable Injections
• West Pharmaceutical Services, Inc.
• CeQur Simplicity

Conclusion

The wearable injectors market is poised for robust growth through 2030, supported by rising chronic disease prevalence, increasing adoption of home-based care, and strong demand for safer drug delivery solutions that minimize needle stick injuries. While high device costs and limited penetration in developing regions may pose challenges, ongoing technological advancements, strategic collaborations, and growing biopharmaceutical adoption are expected to sustain long-term market expansion.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.